NEWTON, Mass.--(BUSINESS WIRE)--Jul. 11, 2012--
Galectin Therapeutics (NASDAQ: GALT), the leading developer of
therapeutics that target galectin proteins to treat fibrosis and cancer,
today announced that it has been added to the Russell Microcap Index
effective at the close of equity markets on June 22, 2012.
Annual reconstitution of Russell Indexes captures the largest U.S.
stocks as of the end of May, ranking them by total market capitalization
to create the Russell 3000® Index and Russell Microcap Index.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
“Addition to the Russell Microcap Index provides greater visibility for
Galectin Therapeutics and its programs in fibrosis and cancer, which
could ultimately result in increased liquidity and a broader shareholder
base for the Company,” said Peter G. Traber, MD, President, CEO and CMO
of Galectin Therapeutics.
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease
and cancer based on the Company's unique understanding of galectin
proteins, key mediators of biologic function. We are leveraging
extensive scientific and development expertise as well as established
relationships with external sources to achieve cost effective and
efficient development. We are pursuing a clear development pathway to
clinical enhancement and commercialization for our lead compounds in
liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events
or future financial performance, and use words such as "may,"
"estimate," "could," "expect" and others. They are based on our current
expectations and are subject to factors and uncertainties which could
cause actual results to differ materially from those described in the
statements. Factors that could cause our actual performance to differ
materially from those discussed in the forward-looking statements
include, among others: incurrence of operating losses since our
inception, uncertainty as to adequate financing of our operations,
extensive and costly regulatory oversight that could restrict or prevent
product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence
on strategic partnerships, product competition, and others stated in
risk factors contained in our SEC filings. We cannot assure that we have
identified all risks or that others may emerge which we do not
anticipate. You should not place undue reliance on forward-looking
statements. Although subsequent events may cause our views to change, we
disclaim any obligation to update forward-looking statements.
About Russell Investments
Russell Investments (Russell) is a global asset manager and one of only
a few firms that offers actively managed, multi-asset portfolios and
services that include advice, investments and implementation. Working
with institutional investors, financial advisors and individuals,
Russell’s core capabilities extend across capital markets insights,
manager research, Indexes, portfolio implementation and portfolio
Russell has approximately $155 billion in assets under management (as of
3/31/2012) and works with 2,400 institutional clients, more than 580
independent distribution partners and advisors, and individual investors
globally. Founded in 1936, Russell is a subsidiary of The Northwestern
Mutual Life Insurance Company.
Source: Galectin Therapeutics Inc.
Galectin Therapeutics Inc.
Maureen Foley, 617-559-0033